Epstein Secrets

invested in or know; Breakthrough Life Sciences Prize recipients; DST technology investment team, and; entities associated with our anchor investor Bill Gates, such as Bill Gates Ventures and the Bill and Melinda Gates Foundation. We are in the process of entering into an agreement with illumine, the leadi

t hard-to-drug targets. Nimbus Discovery harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Nimbus' rob

the for-profit side, Boris led investments in various life science/health care companies such as Foundation Medicine, Research Gate, Schrodinger and Nimbus through Bill Gates Ventures. On the non-for profit side, Boris co-managed BMGF's $1.5 billion strategic investment pool focused on program-related

rts and venture capitalists including, for example, close cooperative relationships with Khosla Ventures and ARCH Venture Partners. • Support from Bill Gates, who we expect to be a significant investor through associated entities which have already provided funding for the first warehoused investment of B

life- science/IT/healthcare companies such as Foundation Medicine and Research Gate, served on the board of directors of Schrodinger, and monitored Nimbus. On the not-for-profit side, Dr. Nikolic co- managed BMGF's $1.5 billion strategic-investment pool, focused on program-related investments in health

Y 2012 and projections for FY 2014 and FY 2015). Questions were asked and a full discussion followed. Mr. Friesner summarized his conversation with Bill Gates in December 2013 on a possible future financing by Mr. Gates. Mr. Guidero stated he would consult with Mr. Gates regarding the potential financing.

ined by Nimbus Discovery, LLC ("Nimbus") in mid-January 2014. Ms. Tran informed the Board that (i) the bridge investors' equity would sit on top of Nimbus' existing investors' equity such that the bridge investors would be paid out in the event of a distribution of proceeds by Nimbus and that (ii) the